How India Exports Adaptogen to the World

As of March 2026, "Adaptogen" is not listed in the FDA's Orange Book, indicating no approved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for this product. Consequently, there are no therapeutic equivalence evaluations or reference listed drugs (RLDs) associated with "Adaptogen" in the U.S. market. This absence suggests that "Adaptogen" has not undergone the FDA's rigorous approval process required for marketing pharmaceutical products in the United States.

Given that "Adaptogen" is not FDA-approved, it is not subject to import alerts specific to this product. However, the importation of unapproved drugs into the U.S. is generally prohibited under the Federal Food, Drug, and Cosmetic Act. Importers must ensure compliance with FDA regulations to avoid potential enforcement actions. The limited export activity from India—comprising 12 shipments by a single exporter, Kerala Ayurveda Limited, primarily to the United States (89.1%)—underscores the niche market presence and potential regulatory challenges faced by "Adaptogen" in the U.S.

In the European Union and the United Kingdom, pharmaceutical products must obtain marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) before commercialization. As of March 2026, there are no records of "Adaptogen" receiving such authorization, indicating it is not approved for sale in these regions.

Compliance with Good Manufacturing Practice (GMP) standards is mandatory for pharmaceutical products in the EU and UK. Manufacturers must adhere to these stringent guidelines to ensure product quality and safety. The absence of marketing authorization for "Adaptogen" suggests that it has not been evaluated against these regulatory standards, potentially limiting its market access in these regions.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. As of the latest edition, "Adaptogen" is not included in this list, indicating it is not recognized as an essential medicine globally.

Furthermore, "Adaptogen" has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, "Adaptogen" is not monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP), suggesting a lack of standardized quality benchmarks for this product.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. "Adaptogen" is not specifically listed under Schedules H, H1, or X, which pertain to prescription drugs with varying degrees of control. This classification implies that "Adaptogen" may be available over-the-counter (OTC) without a prescription.

The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the prices of essential medicines in India. As "Adaptogen" is not listed under the DPCO, it is not subject to price controls, allowing manufacturers to set prices freely. For export purposes, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is typically required, ensuring compliance with export regulations.

A search of the FDA's Orange Book reveals no patents or exclusivity periods associated with "Adaptogen," indicating the absence of patent protection in the U.S. market. This lack of exclusivity suggests that, should "Adaptogen" seek market entry, it would not face patent-related barriers, potentially allowing for generic competition upon approval.

In June 2025, the Indian Ministry of Health and Family Welfare amended the Drugs and Cosmetics Rules to streamline the approval process for traditional medicines, including Ayurvedic products. This regulatory change aims to promote the export of such products by reducing bureaucratic hurdles.

In September 2025, the NPPA announced a revision of the National List of Essential Medicines (NLEM), adding several Ayurvedic formulations. While "Adaptogen" was not included, this development reflects a growing recognition of traditional medicines in India's healthcare system.

In December 2025, the WHO released updated guidelines on the quality control of herbal medicines, emphasizing the need for standardized testing methods. These guidelines are expected to influence regulatory frameworks globally, including in India, potentially impacting the manufacturing and export standards for products like "Adaptogen."

In February 2026, the EMA initiated a public consultation on the integration of traditional herbal medicines into the EU regulatory framework. This move indicates a potential shift towards greater acceptance and regulation of such products within the European market.

In March 2026, the U.S. FDA issued a draft guidance document outlining the regulatory considerations for botanical drug products, including those derived from traditional medicine practices. This guidance aims to clarify the approval pathway for such products, potentially affecting future market entry strategies for "Adaptogen" in the U.S.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of APIs used in Indian drug manufacturing are sourced from China, making the supply chain vulnerable to disruptions. This dependency was highlighted in June 2024 when environmental regulations in China led to the shutdown of several chemical plants, causing a significant shortage of KSMs and subsequent API supply constraints in India.

To mitigate such risks, the Indian government launched the Production Linked Incentive (PLI) scheme in October 2024, aiming to boost domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, reducing import dependence. However, the effectiveness of these initiatives in achieving self-sufficiency remains to be fully realized.

Our proprietary trade data indicates that the export of "Adaptogen" from India is highly concentrated, with KERALA AYURVEDA LIMITED accounting for 100% of the export value. This single-source dependency poses significant risks, as any operational or quality issues within this sole supplier could disrupt the entire supply chain. The PLI scheme, while a step towards diversification, has yet to address this specific concentration risk in the adaptogen market.

Recent geopolitical tensions have further strained pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz following military conflicts led to significant disruptions in the supply of petrochemical feedstocks essential for API synthesis. This event caused delays and increased costs for pharmaceutical manufacturers reliant on these materials. Additionally, the Red Sea conflict in early 2023 disrupted shipping routes, leading to delays in API shipments from Asia to the U.S. and Europe, and causing price fluctuations in the pharmaceutical sector. (pharmasource.global)

• Diversify Supplier Base: Engage multiple suppliers for adaptogen exports to reduce dependency on a single source.

• Enhance Domestic API Production: Accelerate the implementation of the PLI scheme to boost local manufacturing of critical APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact supply chains and develop contingency plans.

• Strengthen Quality Assurance: Implement rigorous quality control measures to ensure compliance with international standards, reducing the risk of regulatory actions.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to mitigate the impact of shipping disruptions in critical regions.

RISK_LEVEL: HIGH